---
document_datetime: 2024-07-05 08:53:18
document_pages: 22
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/baraclude-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: baraclude-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 16.7979869
conversion_datetime: 2025-12-29 19:37:27.858937
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Baraclude

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IA/0079/G            | This was an application for a group of variations. | 04/07/2024                          | n/a                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|             | to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                          |            |     |                 | B.II.b.2.a - Change   |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------|-----------------------|
| IAIN/0078/G | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging | 04/07/2024 |     | Annex II and PL | site                  |
| IA/0077/G   | This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor to an approved test procedure                                                                                                                                                                                                | 04/12/2023 | n/a |                 | changes               |

<div style=\"page-break-after: always\"></div>

| IA/0076            | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                | 03/11/2023   | n/a        |                 |                                   |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------|-----------------------------------|
| PSUSA/1224/ 202203 | Periodic Safety Update EU Single assessment - entecavir                                                                                                                                                                                                                                                                                     | 01/12/2022   | n/a        |                 | PRAC Recommendation - maintenance |
| IB/0074            | B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer                                                                                                                              | 14/06/2022   | n/a        |                 |                                   |
| IAIN/0073          | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                                                                                                                                                                                  | 31/01/2022   | 30/01/2023 | Annex II and PL |                                   |
| IB/0072            | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                            | 16/11/2021   | n/a        |                 |                                   |
| IB/0071/G          | This was an application for a group of variations. B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.b.2.a - Change to importer, batch release | 14/10/2021   | n/a        |                 |                                   |

<div style=\"page-break-after: always\"></div>

|           | and quality control testing of the FP - of a site where batch takes place                                                                                                                                                                                                                                                                                                                                                       |            |            |                 | arrangements Replacement/addition control/testing   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-----------------------------------------------------|
| N/0070    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                | 23/09/2021 | 30/01/2023 | PL              |                                                     |
| IB/0068   | B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation                                                                                                                                                                                                                                                                                                                                                    | 21/06/2021 | n/a        |                 |                                                     |
| IA/0069   | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                    | 17/06/2021 | n/a        |                 |                                                     |
|           | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure | 20/10/2020 | n/a        |                 | IB/0067/G                                           |
| IG/1223/G | This was an application for a group of variations. A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release B.II.b.2.c.1 - Change to importer, batch release and quality control testing of the FP -                                                                                                                                                          | 17/04/2020 | 22/01/2021 | Annex II and PL | arrangements                                        |

<div style=\"page-break-after: always\"></div>

|         | Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0064 | Update of sections 4.8 and 5.1 of the SmPC in order to reflect the completion of the two paediatric studies AI463028 (Evaluation of the pharmacokinetics, safety, tolerability and efficacy of Entecavir (ETV) in paediatric subjects with chronic hepatitis B virus (HBV) infection who are HBeAg-Positive) and AI463189 (A Comparative study of the antiviral efficacy and safety of ETV versus placebo in paediatric subjects with Chronic Hepatitis B Virus (HBV) infection who are HBeAg-Positive). Section 5.1 is also updated to reflect the outcome of study AI463080 (Randomized, observational study of ETV to assess long-term outcomes associated with nucleoside/nucleotide monotherapy for patients with Chronic HBV Infection: The REALM Study). Moreover, section 5.2 of the SmPC is also updated to remove information on the pharmacokinetics of entecavir in lamivudine-experienced paediatric patients, at the request of the CHMP; and section 5.3 to make reference to the clinical data in section 5.1 in respect to carcinogenicity. The RMP version 15 has also been approved, which implements Revision 2 of the EU-RMP template. In addition, the Marketing authorisation holder (MAH) took the opportunity to bring the PI in line with the latest QRD template version 10.1 and to | 17/04/2020 | 22/01/2021 | SmPC, Annex II, Labelling and PL | Study 080 was a randomized, observational open-label Phase 4 study to assess long-term risks of entecavir (ETV) treatment (n=6,216) or other standard of care hepatitis B virus (HBV) nucleoside (acid) treatment (non-ETV) (n=6,162) for up to 10 years in subjects with chronic HBV (CHB) infection. The principal clinical outcome events assessed in the study were overall malignant neoplasms (composite event of hepatocellular carcinoma (HCC) and non-HCC malignant neoplasms), liver related HBV disease progression, non-HCC malignant neoplasms, HCC, and deaths, including liver related deaths. Results from study 080 suggest that ETV was not associated with an increased risk of malignant neoplasms compared to use of non-ETV, as assessed by either the composite endpoint of overall malignant neoplasms (ETV n=331, non-ETV n=337; HR=0.93 [0.8-1.1]), or the individual endpoint of non-HCC malignant neoplasm (ETV n=95, non-ETV n=81; HR=1.1 [0.82-1.5]). The reported events for liver-related HBV disease progression and HCC were comparable in both ETV and non-ETV groups. The most commonly reported malignancy in both ETV and non- ETV groups was HCC followed by gastrointestinal malignancies. |

<div style=\"page-break-after: always\"></div>

|           | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                 |            |            |                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0063   | Update of section 4.8 of the SmPC in order to add neutropenia as a very common adverse reaction in paediatric patients, based on the cases reported from both paediatric studies AI463189 and AI463028. The package leaflet is updated accordingly. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority | 30/01/2020 | 22/01/2021 | SmPC and PL               | Neutropenia is added as a very common adverse reaction in paediatric patients, based on the cases reported from both paediatric studies AI463189 and AI463028. Study AI463189, there were 14 neutropenia cases out of 119 patients treated with ETV 0.015 mg/kg up to 0.5 mg daily through 48 weeks, whereas there were 2 neutropenia cases out of 60 patients treated with placebo during the same period. In AI463028, there were 2 neutropenia cases out of 24 lamivudine treatment-naïve patients treated with ETV 0.015 mg/kg up to 0.5 mg daily through 48 weeks. |
| IG/1193   | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                | 17/01/2020 | n/a        |                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| N/0062    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                  | 13/05/2019 | 22/01/2021 | PL                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| IG/1059   | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                                                                                                                                                        | 15/02/2019 | 25/03/2019 | SmPC, Labelling and PL    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| IAIN/0060 | B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking                                                                                                                                                                                                               | 28/01/2019 | 25/03/2019 | PL                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| II/0059   | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance                                                                                                                                                                                                                                                                                      | 13/09/2018 | 25/03/2019 | SmPC, Annex II, Labelling |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

|           | data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |            | and PL           |                                                                                                              |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------|--------------------------------------------------------------------------------------------------------------|
| N/0058    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                           | 26/06/2018 | 25/03/2019 | Labelling and PL |                                                                                                              |
| IB/0057/G | This was an application for a group of variations. B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                             | 13/04/2018 | n/a        |                  |                                                                                                              |
| IA/0056/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place | 12/02/2018 | n/a        |                  |                                                                                                              |
| II/0053   | Submission of the final study report for study AI463080, a long-term outcomes study (10 years),                                                                                                                                                                                                                                                                                                                                                                                                                                            | 11/01/2018 | n/a        |                  | The final analysis report with data from study AI463080 provides evidence that the risk of overall malignant |

<div style=\"page-break-after: always\"></div>

|           | to assess the rates of malignant neoplasm (all, non- hepatocellular carcinoma, and hepatocellular carcinoma), liver-related events of HBV disease progression, and mortality. Risk Management Plan Version 14 has been updated accordingly. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |     | neoplasms (all, non-hepatocellular carcinoma or hepatocellular carcinoma), liver-related hepatitis B virus disease progression and death does not differ between long-term entecavir use - and non- entecavir -treated subjects. Therefore no amendment to the product information was warranted based on these data.   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0054/G | This was an application for a group of variations. B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process | 20/12/2017 | n/a |                                                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

|                    | and/or limits of the finished product - Tightening of specification limits                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |     |                                   |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| IA/0055            | B.II.e.4.a - Change in shape or dimensions of the container or closure (immediate packaging) - Non- sterile medicinal products                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 18/12/2017 | n/a |                                   |
| PSUSA/1224/ 201703 | Periodic Safety Update EU Single assessment - entecavir                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 26/10/2017 | n/a | PRAC Recommendation - maintenance |
| IA/0051/G          | This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.f - Change in test procedure for the finished product - To reflect compliance with the Ph. Eur. and remove reference to the outdated internal test method and test method number B.II.d.2.f - Change in test procedure for the finished product - To reflect compliance with the Ph. Eur. and remove reference to the outdated internal test method and test method number B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier | 14/02/2017 | n/a |                                   |
| IB/0050/G          | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 14/04/2016 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|         | manufacturer of a novel excipient B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                      |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0049 | Update of sections 4.8 and 5.1 of the SmPC to add long term efficacy, safety and resistance data on the paediatric population from the AI463189 'expanded cohort' (180 subjects) study; the RMP (v.13) is updated accordingly. In addition, the MAH took the opportunity to combine the SmPCs of Baraclude 0.5 mg tablets and Baraclude 1 mg tablets and to update Annex A to include unit dose blisters. The Package Leaflet (PL) is updated to reflect a change in the contact details of a local representative. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 01/04/2016 | 03/03/2017 | SmPC and PL | In this variation, the MAH provided week 96 efficacy, safety and resistance data from the AI463189 'expanded cohort' (180 subjects). This updated interim analysis does not alter any of the main conclusions reached in the recent assessment of variation II/41, in which a paediatric extension of indication for Baraclude was granted based on the presently discussed AI463189 study. The paediatric resistance assessment is based on data from nucleoside- treatment-naive paediatric patients with HBeAg-positive chronic HBV infection in two ongoing clinical trials (028 and 189). The two trials provide resistance data in 183 patients treated and monitored in Year 1 and 180 patients treated and monitored in Year 2. Genotypic evaluations were performed for all patients with available samples who had virologic breakthrough through Week 96 or HBV DNA ≥ 50 IU/ml at Week 48 or Week 96. During Year 2, genotypic resistance to ETV was detected in 2 patients (1.1% cumulative probability of resistance through Year 2). |

<div style=\"page-break-after: always\"></div>

| N/0048   | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                            | 04/11/2015   | 03/03/2017   | PL          |                                                                     |
|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------|---------------------------------------------------------------------|
| IG/0602  | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                                                                                                                            | 11/09/2015   | n/a          |             |                                                                     |
| IA/0046  | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                         | 17/12/2014   | n/a          |             |                                                                     |
| IA/0045  | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                  | 24/10/2014   | n/a          |             |                                                                     |
| II/0041  | Extension of indication to include treatment of chronic HBV infection in paediatric patients from 2 to <18 years of age with compensated liver disease and evidence of active viral replication and persistently elevated serum ALT levels. Consequently, the MAH proposed the update of sections 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC. The Package Leaflet was proposed to be updated in accordance. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or | 24/07/2014   | 22/08/2014   | SmPC and PL | Please refer to the CHMP assessment report EMEA/H/C/000623/II/0041. |

<div style=\"page-break-after: always\"></div>

| IAIN/0044   | B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking                                                                                                                                                                                                                                                                                                                                                                                                | 12/06/2014   | 22/08/2014   | SmPC and PL           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0043     | Submission of the final study report, 5 years follow- up of Study AI463048: Comparison Of The Efficacy And Safety Of Entecavir Versus Adefovir In Subjects Chronically Infected With Hepatitis B Virus And Evidence Of Hepatic Decompensation. This submission fulfils a post-authorisation measure. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                 | 25/04/2014   | n/a          |                       | The study AI463048 final analyses provide a high-level descriptive and limited understanding of the clinical outcomes that can be observed with long-term treatment of patients with decompensated liver function due to chronic HBV. Three key clinical outcome events of interest in this decompensated population (death; the diagnosis of hepatocellular carcinoma [HCC]; and 'disease progression' defined by the occurrence of specified adverse events [AEs] of decompensation) were assessed over the entire study observation period. No signals of specific concerns have been identified. Therefore, no update of the product information for Baraclude is needed in the view of these |
| II/0042     | Update of sections 4.2 and 4.4 of the SmPC to initiate combination therapy with entecavir plus a second antiviral agent, instead of entecavir monotherapy, in patients with lamivudine-resistant hepatitis B virus infection. Section 4.1 of the SmPC was updated to include a cross reference to section 4.2 with respect to patients with lamivudine- refractory hepatitis B. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet. Furthermore, the PI is being brought in line with the latest QRD template version 9. | 23/01/2014   | 22/08/2014   | SmPC, Annex II and PL | The use of entecavir in patients with prior lamivudine resistance, is well-known to cause a decrease in sensitivity to entecavir, as well as a lowering of the barrier to further resistance. The product information already contained a warning on this issue that was strengthened. When starting therapy in patients with a documented history of lamivudine-resistant HBV, combination use of entecavir plus a second antiviral agent (which does not share cross resistance with either lamivudine or entecavir) should be considered in preference to entecavir monotherapy.                                                                                                               |

<div style=\"page-break-after: always\"></div>

|           | the Summary of Product Characteristics, Annex II and Package Leaflet. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                             |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0039/G | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                               | 21/12/2012 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| IG/0254   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                   | 17/12/2012 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| II/0038   | Update of section 5.1 of the SmPC to include clinical study data on liver transplant recipients. The PL is updated in accordance. In addition, the MAH took the opportunity to update the list of local representatives in the PL. Furthermore, the PI is being brought in line with the latest QRD template version 8.1. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data | 20/09/2012 | 24/10/2012 | SmPC, Annex II, Labelling and PL | The MAH submitted the final results of study AI463109, a non-comparative study conducted in 65 patients that had a post-orthotopic liver transplant due to hepatitis B related liver failure or hepatocellular carcinoma. The dose of ETV evaluated was 1.0 mg once daily, which was considered appropriate to the patient population studied. There were no virological recurrences by the protocol-specified definition (plasma HBV-DNA ≥ 50 IU/mL). The clinical implications of HBV recurrence are still unclear; therefore a description of this observation is included in the SmPC. There were no new or unexpected safety concerns have been identified in the population studied. The CHMP |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                         |            |            |                       | considered that the clinical benefit-risk for the use of entecavir in patients with post-orthotopic liver transplant is favourable; therefore a description of study outcomes in the Product Information was accepted.                                                                                                                            |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0035  | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                 | 17/03/2011 | 12/05/2011 | SmPC, Annex II and PL |                                                                                                                                                                                                                                                                                                                                                   |
| IB/0037 | B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the currently approved batch size                                                                                                                             | 28/04/2011 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                   |
| IA/0036 | C.I.9.e - Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the major contractual arrangements with other persons or organisations involved in the fulfilment of pharmacovigilance obligations and described in the DD                              | 16/03/2011 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                   |
| II/0033 | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                                                                                                                                                          | 20/01/2011 | 28/02/2011 | SmPC, Annex II and PL | Please refer to the Assessment Report: Baraclude-H-623- II-33-AR                                                                                                                                                                                                                                                                                  |
| IA/0034 | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                           | 12/11/2010 | n/a        | Annex II and PL       |                                                                                                                                                                                                                                                                                                                                                   |
| II/0030 | Update of sections 4.8 and 4.4 of the SmPC to include a description of the adverse reaction 'lactic acidosis' as requested by CHMP further to assessment of PSUR 7. In addition, the MAH has taken the opportunity to add 'increased transaminases' as a postmarketing event in section | 22/07/2010 | 26/08/2010 | SmPC, Annex II and PL | Cases of lactic acidosis have been reported, often in association with hepatic decompensation, other serious medical conditions or drug exposures. Due to a number of emerging case reports of lactic acidosis and acidemia in patients on entecavir therapy, this adverse event has been included in the product information. Lactic acidosis is |

<div style=\"page-break-after: always\"></div>

|           | 4.8. The Product Information is updated in accordance with QRD guidelines and the list of representatives is updated in the PL. The version number of the RMP is also updated in Annex II. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data                                                          |            |     |          | considered a putative class effect of nucleoside analogues as they may interfere with the functioning of DNA polymerase gamma. Furthermore a cumulative review of cases with reported events specifically related to hepatic transaminase elevations was undertaken to evaluate the adequacy of information contained in the product information with respect to such events. Based on this review \"transaminases increased\" has been included as an adverse reaction.   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0032   | C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system                                                                                                                                                                                                                     | 11/08/2010 | n/a | Annex II |                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| IA/0031/G | This was an application for a group of variations. B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure | 30/07/2010 | n/a |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| IA/0029/G | This was an application for a group of variations. C.I.9.b - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the contact details of the QPPV C.I.9.h - Changes to an existing pharmacovigilance                                                                                                                                                                       | 12/03/2010 | n/a | Annex II |                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

|         | system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system                                                                                                                                                                                                                                                                                 |            |            |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0027  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                    | 24/09/2009 | n/a        | PL                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| IA/0028 | IA_11_a_Change in batch size of active substance or intermediate - up to 10-fold                                                                                                                                                                                                                                                                                                                                    | 21/09/2009 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| II/0026 | Update of section 4.8 of the SPC and section 4 of the PL to include alopecia and anaphylactoid reactions as requested by the CHMP further to the assessment of PSUR 5. In addition, section 4.9 is updated to reflect that overdose reports have been received in PSURs. Annex II reflects the current Risk Management Plan version (version 3.0). Update of Summary of Product Characteristics and Package Leaflet | 25/06/2009 | 03/08/2009 | SmPC, Annex II and PL | A cumulative review assessed in PSUR 5 (covering period: 29.3.08 - 28.9.08) identified a total of 30 spontaneous cases of alopecia. Two cases were serious. In ten cases the time to onset of alopecia was between 1 and 3 months after initiation of entecavir treatment. Alopecia is now listed as an adverse reaction to entecavir. Alopecia has been associated with hepatitis B therapies. As regards anaphylactoid reactions, 2 cases were reported in PSUR 5: one of drug hypersensitivity and one of hypersensitivity being the first cases life-threatening. Based on these cases, anaphylactoid reaction has been added to the list of adverse reactions to entecavir treatment. Section 4.8 of the SPC and section 4 of the PL are amended in accordance. Overdose reports have been received and included in the PSURs for Baraclude, therefore section 4.9 of the SPC has been updated to reflect these reports. |
| II/0025 | Change in the formulation of the finished product. Change in formulation                                                                                                                                                                                                                                                                                                                                            | 29/05/2009 | 07/07/2009 | SmPC and PL           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| II/0020 | Update of section 5.1 with long-term data on the                                                                                                                                                                                                                                                                                                                                                                    | 23/04/2009 | 08/06/2009 | SmPC                  | Two-hundred and three HBeAg positive and HBeAg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

|         | effects of entecavir on liver necroinflammation and fibrosis as evaluated in a subset of nucleos(t)ide- naive HBeAg-positive and HBeAg-negative chronic HBV subjects from Study AI463901. Update of Summary of Product Characteristics   |            |            |          | negative patients from the pivotal studies AI463022 and AI463027, respectively were eligible to roll-over to study AI463901 and continued treatment with entecavir (ETV) but at an increased dose of 1 mg once daily and initially also with lamivudine. Of the fifty seven patients with evaluable baseline and long-term biopsies, 55 had histologic improvement and 50 had a ?1-point decrease in Ishak fibrosis score. Of the 43 with a baseline Ishak fibrosis score of ?2, 58 % had a ?2-point decrease. Regression of fibrosis was seen in all 10 patients with advanced fibrosis or cirrhosis. At the time of the biopsy, all 57 patients had HBV DNA < 300 copies/ml and 49/57 (86%) had serum ALT ?1 X ULN. All 57 patients remained positive for HBsAg. The results of this study demonstrated that long-term ETV therapy for approximately 6 years in nucleoside-naïve patients with chronic hepatitis B resulted in improvement of liver necroinflammation and fibrosis. The clinical benefit of long term viral suppression of HBV has now been confirmed with long-term histology data.   |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0022 | IB_33_Minor change in the manufacture of the finished product                                                                                                                                                                            | 24/03/2009 | n/a        |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| IA/0024 | IA_28_Change in any part of primary packaging material not in contact with finished product                                                                                                                                              | 05/03/2009 | n/a        |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| IA/0023 | IA_08_a_Change in BR/QC testing - repl./add. of batch control/testing site                                                                                                                                                               | 05/03/2009 | n/a        |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| II/0021 | Update of Detailed Description of the Pharmacovigilance System                                                                                                                                                                           | 22/01/2009 | 26/02/2009 | Annex II | The Detailed Description of the Pharmacovigilance System has been updated (Version 3.0) to reflect the change of the Qualified Person for Pharmacovigilance (QPPV) as well as to                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

|         | Update of DDPS (Pharmacovigilance)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |            |                   | notify other changes to the DDPS performed since the last approved version. Consequently, Annex II has been updated using the standard text with the new version number of the agreed DDPS.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0019 | Update of section 4,1, 4.2, 4.4 and 5.1 of the SPC to reflect the results of long term resistance data from \"Year 5 Resistance Summary Report\" which includes a cumulative review of all viral variants observed to have the two specified substitutions at rtI169 and rtV173. In addition, Annex IIB is updated under \"Other Conditions\", to include standard text with relevant version numbers of the Detailed Description of the Pharmacovigilance System as well as the Risk Management Plan. Update of Summary of Product Characteristics | 18/12/2008 | 10/02/2009 | SmPC and Annex II | The 5-year resistance data suggests that the rate of entecavir resistance in nucleoside-naïve patients is very low and maintained through five years of therapy. The cumulative probability of genotypic entecavir resistance (ETVr) and virologic breakthrough due to resistance in nucleoside-naïve patients was 1.2% and 0.8%, respectively. However, in lamivudine-refractory patients, the rate of resistance increased with time and the cumulative probability of genotypic ETVr is high: 6%, 15%, 36%, 47% and 51% in year 1 through 5, respectively. The cumulative probability of virologic breakthroughs with ETVr was 1%, 11%, 27%, 41% and 44% over the same time frame. Based on the data provided and taking into account the current treatment options available for lamivudine- refractory patients, it became clear that the eventual place of ETV in LVD-refractory patients is restricted to those with low baseline HBV DNA and those with an early response at week 24. These characteristics were shown to predict a lower risk of subsequent development of resistance on long-term ETV treatment. |
| II/0017 | To update section 4.8 of the Summary Product Characteristics to add \"rash\" to the post marketing subsection following assessment of Baraclude's PSUR 3 covering the period 29 March 2007 - 28 September 2007. Section 4 of the PL is updated accordingly. In addition, an updated version (version 2.5) of the                                                                                                                                                                                                                                  | 26/06/2008 | 22/08/2008 | SmPC and PL       | Further to the assessment of post-marketing and clinical safety data and review of 26 non-serious reported cases of \"rash\" that occurred during the period covered by the entecavir 3rd PSUR, no definitive information about causality adjudication between entecavir and rash was provided. However, the times of occurrence of \"rash\" indicated a relationship. The product information for                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

|         | Detailed Description of the Pharmacovigilance System was included in this submission. Furthermore, the MAH updated section 6 \"further information\" of the PL with the contact details for its local representative in Romania and made some editorial changes (spelling corrections) in the BG, ES, ET, FI, FR, HU, IT, LV, NO, PL, RO and SK product information. Update of Summary of Product Characteristics and Package Leaflet   |            |            |                        | entecavir was updated to include \"rash\" in the undesirable effects section identified during post-approval use of Baraclude. The updated version of the DDPS provided was written according to the structure described in Volume 9A.   |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0018 | IA_12_a_Change in spec. of active subst./agent used in manuf. of active subst. - tightening of spec. IB_13_b_Change in test proc. for active substance - other changes (replacement/addition)                                                                                                                                                                                                                                         | 27/05/2008 | n/a        |                        |                                                                                                                                                                                                                                        |
| IA/0016 | IA_13_a_Change in test proc. for active substance - minor change                                                                                                                                                                                                                                                                                                                                                                      | 19/02/2008 | n/a        |                        |                                                                                                                                                                                                                                        |
| IB/0014 | IB_41_a_02_Change in pack size - change in no. of units outside range of appr. pack size                                                                                                                                                                                                                                                                                                                                              | 30/01/2008 | 30/01/2008 | SmPC, Labelling and PL |                                                                                                                                                                                                                                        |
| IB/0013 | IB_41_a_02_Change in pack size - change in no. of units outside range of appr. pack size                                                                                                                                                                                                                                                                                                                                              | 30/01/2008 | 30/01/2008 | SmPC, Labelling and PL |                                                                                                                                                                                                                                        |
| IA/0015 | IA_43_a_01_ Add./replacement/del. of measuring or administration device - addition or replacement                                                                                                                                                                                                                                                                                                                                     | 14/01/2008 | n/a        |                        |                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

| II/0007   | Update of Summary of Product Characteristics and Package Leaflet.                                                                                                                                                                                             | 18/10/2007   | 21/11/2007   | SmPC and PL     | New analysis of the in vitro/cell culture data and clinical data available confirm the signal that the use of entecavir as monotherapy in co-infected patients is associated with   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0012   | IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site IA_08_b_02_Change in BR/QC testing - repl./add. manuf. responsible for BR - incl. BC/testing                                                                                         | 29/10/2007   | n/a          | Annex II and PL |                                                                                                                                                                                     |
| IA/0011   | IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site IA_07_b_01_Replacement/add. of manufacturing site: Primary packaging site - Solid forms IA_08_b_02_Change in BR/QC testing - repl./add. manuf. responsible for BR - incl. BC/testing | 29/10/2007   | n/a          | Annex II and PL |                                                                                                                                                                                     |
| II/0010   | Quality changes                                                                                                                                                                                                                                               | 18/10/2007   | 24/10/2007   |                 |                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| II/0005   | To update section 5.1 of the SPC on resistance data from a longer follow-up period of 144 weeks, supported by the \"year 3 resistance summary report\". Furthermore, the MAH took the opportunity of this variation to update the local representative contact in Denmark. Update of Summary of Product Characteristics and Package Leaflet   | 19/07/2007   | 22/08/2007   | SmPC and PL   | The 3-year resistance report summarises the current understanding of entecavir resistance (ETVr) emergence in patients infected with hepatitis B virus (HBV) infection. The evaluation was based on genotypic and phenotypic data from patients treated with entecavir (ETV) for up to three years (Week 144) in 6 clinical trials conducted in nucleoside-treatment-naïve and lamivudine (LVD)- refractory patients treated with 0.5 mg or 1.0 mg ETV, respectively. ETV therapy has been shown to be associated with establishment of a high genetic barrier to resistance in nucleoside-naïve patients. In contrast, in LVD-refractory patients the genetic barrier of ETVr is decreased requiring only a single aminoacid substitution in LVDr HBV. In this LVD-refractory population genotypic resistance increased with time and emerged in 6%, 8%, and 19% of patients in years 1, 2, and 3. This corresponds to a cumulative probability of genotypic ETVr of 6%, 15% and 35% respectively. The CHMP considers that the findings presented in this 3- year resistance report do not change the risk-benefit profile of entecavir.   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0009   | IA_38_a_Change in test procedure of finished product - minor change to approved test procedure                                                                                                                                                                                                                                              | 02/08/2007   | n/a          |               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| IA/0008   | IA_38_a_Change in test procedure of finished product - minor change to approved test procedure                                                                                                                                                                                                                                              | 02/08/2007   | n/a          |               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| II/0006   | Quality changes                                                                                                                                                                                                                                                                                                                             | 24/05/2007   | 30/05/2007   |               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| II/0002   | To update sections 4.2 and 4.4 of the SPC with                                                                                                                                                                                                                                                                                              | 22/03/2007   | 26/04/2007   | SmPC, Annex   | Entecavir is mainly eliminated by the kidney. Therefore,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|         | information on a alternative dosing schedule proposed for patients with renal impairment (including patients undergoing haemodialysis) in addition to the current dosing scheme with the Oral Solution. Sections 2 and 3 of the PL were updated accordingly. Furthermore, the MAH took the opportunity to update the contact details for the local representatives in Belgium, Denmark, Greece, Latvia, Luxembourg, Norway, Portugal and Spain in the PL, to update the Product Information according to the latest EMEA/QRD template and to make minor administrative and editorial corrections to the annexes. Update of Summary of Product Characteristics and Package Leaflet   |            |     | II, Labelling and PL   | patients with renal impairment may require dose adjustment depending on the degree of their renal impairment. The original dosing recommendations for patients with renal impairment consisted of adjusting the daily dose of oral solution. These recommendations were based on pharmacokinetic data from a clinical study. This variation proposes an alternative dosing schedule for patients with renal impairment in addition to the current one with the oral solution, based on additional analyses performed with data from the same study. This alternative dosage recommendation consists of increasing the dosage interval between two doses of Baraclude film-coated tablets depending on the degree of renal impairment. However, this alternative is recommended only when the oral solution is not available. Furthermore, since the safety and effectiveness of the proposed dose modifications have not been clinically evaluated, the virological response should be closely monitored. This information was included in the SPC and the possibility of an alternative dosing schedule was also mentioned in the PL.   |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0003  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 06/04/2007 | n/a | PL                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| IA/0004 | IA_13_a_Change in test proc. for active substance - minor change                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 07/02/2007 | n/a |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| IA/0001 | IA_11_a_Change in batch size of active substance or intermediate - up to 10-fold                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 13/07/2006 | n/a |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |